| Total N. (%) |
---|---|
No. of patients | 50 |
Sex | Â |
   Male/Female | 31/19 |
Age, years | Â |
   median | 63 |
   range | 40-73 |
   ≥ 65 years | 24 (48) |
WHO Performance Status | Â |
   0 | 48 (96) |
   1-2 | 2 (4) |
Metastatic disease | Â |
   metachronous | 15 (30) |
   synchronous | 35 (70) |
Primary tumor | Â |
   colon | 24 (48) |
   rectum | 26 (52) |
Sites of metastases | Â |
   liver | 33 (66) |
   lung | 10 (20) |
   lymph nodes | 17 (34) |
   local | 10 (20) |
   Other | 5 (10) |
No. of involved sites | Â |
   1 | 32 (64) |
   ≥ 2 | 18 (36) |
Single metastatic sites | Â |
   liver | 22 (44) |
   lung | 3 (6) |
   lymph nodes | 3 (6) |
   local | 4 (8) |
Liver metastases | Â |
   single | 11 (22) |
   multiple | 22 (44) |
Previous adjuvant chemotherapy: | 9 (18) |
   FA/5-FU bolus | 4 (8) |
   Capecitabine | 1 (2) |
   FOLFOX4 | 4 (8) |
Previous radiotherapy: | 6 (12) |
   RT alone | 2 (4) |
   RT+CT (5-FU c.i.) | 3 (6) |
   RT+CT (XELOX) | 1 (2) |